168 related articles for article (PubMed ID: 32167591)
1. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
Wang H; Gong Y; Liang L; Xiao L; Yi H; Ye M; Roy M; Xia J; Zhou W; Yang C; Shen X; Zhang B; Li Z; Liu J; Zhou H; Xiao X
Br J Haematol; 2020 Jun; 189(6):1151-1164. PubMed ID: 32167591
[TBL] [Abstract][Full Text] [Related]
2. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Structural Optimization of Lycorine-Derived Phenanthridine Derivatives as Wnt/β-Catenin Signaling Pathway Agonists.
Chen DZ; Jing CX; Cai JY; Wu JB; Wang S; Yin JL; Li XN; Li L; Hao XJ
J Nat Prod; 2016 Jan; 79(1):180-8. PubMed ID: 26714198
[TBL] [Abstract][Full Text] [Related]
4. Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.
Roy M; Liang L; Xiao X; Peng Y; Luo Y; Zhou W; Zhang J; Qiu L; Zhang S; Liu F; Ye M; Zhou W; Liu J
Theranostics; 2016; 6(12):2209-2224. PubMed ID: 27924158
[TBL] [Abstract][Full Text] [Related]
5. Lycorine possesses notable anticancer potentials in on-small cell lung carcinoma cells via blocking Wnt/β-catenin signaling and epithelial-mesenchymal transition (EMT).
Sun Y; Wu P; Sun Y; Sharopov FS; Yang Q; Chen F; Wang P; Liang Z
Biochem Biophys Res Commun; 2018 Jan; 495(1):911-921. PubMed ID: 29127013
[TBL] [Abstract][Full Text] [Related]
6. Lycorine induces cell death in MM by suppressing Janus Kinase/signal transducer and activator of transcription via inducing the expression of SOCS1.
Jin Z; Zhou S; Zhang Y; Ye H; Jiang S; Yu K; Ma Y
Biomed Pharmacother; 2016 Dec; 84():1645-1653. PubMed ID: 27847203
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
[TBL] [Abstract][Full Text] [Related]
9. Lycorine inhibits melanoma cell migration and metastasis mainly through reducing intracellular levels of β-catenin and matrix metallopeptidase 9.
Zhang P; Zhang M; Yu D; Liu W; Hu L; Zhang B; Zhou Q; Cao Z
J Cell Physiol; 2019 Jul; 234(7):10566-10575. PubMed ID: 30565685
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest.
Li Y; Liu J; Tang LJ; Shi YW; Ren W; Hu WX
Oncol Rep; 2007 Feb; 17(2):377-84. PubMed ID: 17203177
[TBL] [Abstract][Full Text] [Related]
11. Identification of molecular anti-metastasis mechanisms of lycorine in colorectal cancer by RNA-seq analysis.
Gao L; Feng Y; Ge C; Xu X; Wang S; Li X; Zhang K; Wang C; Dai F; Xie S
Phytomedicine; 2021 May; 85():153530. PubMed ID: 33761445
[TBL] [Abstract][Full Text] [Related]
12. Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/β-catenin signaling attenuation.
Choi PJ; O Y; Her JH; Yun E; Song GY; Oh S
Leuk Res; 2017 Sep; 60():103-108. PubMed ID: 28772205
[TBL] [Abstract][Full Text] [Related]
13. Protein mass spectrometry reveals lycorine exerting anti-multiple-myeloma effect by acting on VDAC2 and causing mitochondrial abnormalities.
Yi H; Shen X; Wang H; Luo S; Guo W; Chen P; Hu L; Liang L; Gong Y; Xiao X; Liu J
Biotechnol Lett; 2021 Mar; 43(3):537-546. PubMed ID: 33386501
[TBL] [Abstract][Full Text] [Related]
14. Lycorine induces programmed necrosis in the multiple myeloma cell line ARH-77.
Luo Y; Roy M; Xiao X; Sun S; Liang L; Chen H; Fu Y; Sun Y; Zhu M; Ye M; Liu J
Tumour Biol; 2015 Apr; 36(4):2937-45. PubMed ID: 25487618
[TBL] [Abstract][Full Text] [Related]
15. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma cancer stem cells.
Gao M; Kong Y; Yang G; Gao L; Shi J
Oncotarget; 2016 Jun; 7(23):35466-77. PubMed ID: 27007154
[TBL] [Abstract][Full Text] [Related]
17. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
Schmeel FC; Schmeel LC; Kim Y; Schmidt-Wolf IG
Hematol Oncol; 2014 Dec; 32(4):197-204. PubMed ID: 24470348
[TBL] [Abstract][Full Text] [Related]
18. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.
Yi H; Liang L; Wang H; Luo S; Hu L; Wang Y; Shen X; Xiao L; Zhang Y; Peng H; Dai C; Yuan L; Li R; Gong F; Li Z; Ye M; Liu J; Zhou H; Zhang J; Xiao X
Cancer Lett; 2021 Nov; 520():307-320. PubMed ID: 34390764
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
20. Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.
Hu M; Peng S; He Y; Qin M; Cong X; Xing Y; Liu M; Yi Z
Oncotarget; 2015 Jun; 6(17):15348-61. PubMed ID: 25915156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
